ABSTRACT
PURPOSE: To investigate the incidence and prognostic factors of ocular sequelae in Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) cases arising between 2016 and 2018 in Japan, and compare the findings with those presented in the previous 2005-2007 survey. DESIGN: Retrospective, national trend survey. METHODS: Dermatologic case report forms (CRFs) (d-CRFs) were sent to 257 institutions that treated at least 1 SJS/TEN case, and 508 CRFs were collected from 160 institutions. Ophthalmologic CRFs (o-CRFs) regarding patient demographic data, onset date, ocular findings (first appearance, day of worst severity, and final follow-up), topical treatment (betamethasone), outcome (survival or death), and ocular sequelae (visual disturbance, eye dryness) were sent to the ophthalmologists in those 160 institutions. The results of this survey were then compared with that of the previous 2005-2007 survey. RESULTS: A total of 240 cases (SJS/TEN: 132/108) were included. The incidence of ocular sequelae incidence was 14.0%, a significant decrease from the 39.2% in the previous survey (SJS/TEN: 87/48). In 197 (82.1%) of the cases, systemic treatment was initiated within 3 days after admission, an increase compared to the previous survey (ie, treatment initiated in 82 [60.7%] of 135 cases). Of the 85 cases with an Acute Ocular Severity Score of 2 and 3, 62 (72.9%) received corticosteroid pulse therapy and 73 (85.9%) received 0.1% betamethasone therapy; an increase compared to the 60.0% and 70.8%, respectively, in the previous survey. Ocular-sequelae-associated risk factors included Acute Ocular Severity Score (P < .001) and specific year in the survey (P < .001). CONCLUSIONS: The ophthalmologic prognosis of SJS/TEN has dramatically improved via early diagnosis, rapid assessment of acute ocular severity, and early treatment.
ABSTRACT
BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening, severe mucocutaneous adverse reactions. Severity prediction at early onset is urgently required for treatment. However, previous prediction scores have been based on data of blood tests. OBJECTIVE: This study aimed to present a novel score that predicts mortality in patients with SJS/TEN in the early stages based on only clinical information. METHODS: We retrospectively evaluated 382 patients with SJS/TEN in a development study. A clinical risk score for TEN (CRISTEN) was created according to the association of potential risk factors with death. We calculated the sum of these risk factors using CRISTEN, and this was validated in a multinational survey of 416 patients and was compared with previous scoring systems. RESULTS: The significant risk factors for death in SJS/TEN comprised 10 items, including patients' age of ≥65 years, ≥10% body surface area involvement, the use of antibiotics as culprit drugs, the use of systemic corticosteroid therapy before the onset, and mucosal damage affecting the ocular, buccal, and genital mucosa. Renal impairment, diabetes, cardiovascular disease, malignant neoplasm, and bacterial infection were included as underlying diseases. The CRISTEN model showed good discrimination (area under the curve [AUC] = 0.884) and calibration. In the validation study, the AUC was 0.827, which was statistically comparable to those of previous systems. CONCLUSION: A scoring system based on only clinical information was developed to predict mortality in SJS/TEN and was validated in an independent multinational study. CRISTEN may predict individual survival probabilities and direct the management and therapy of patients with SJS/TEN.
ABSTRACT
BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening severe cutaneous adverse reactions (SCARs). Sepsis has been shown to be the main cause of death in SJS/TEN. The European SCAR study reported that 14.8 % of SJS/TEN patients were receiving systemic steroid therapy for their underlying condition prior to onset. However, it remained unclear whether this factor affected the mortality rate. OBJECTIVE: This study was performed to identify risk factors for sepsis in SJS/TEN patients. In addition, we compared patients who had and had not received systemic steroid therapy for their underlying condition. METHODS: A primary survey regarding the numbers of SJS/TEN patients between 2016 and 2018 was sent to 1205 institutions in Japan. A secondary survey seeking more detailed information was sent to institutions reporting SJS/TEN patients. We analyzed 315 SJS patients and 174 TEN patients using a logistic regression model, Wilcoxon's rank-sum test, χ2 test, and Fisher's exact test. RESULTS: Significant risk factors for sepsis included TEN, diabetes, and intensive care unit (ICU) admission. The mortality rate was significantly higher among patients with sepsis. Patients who had received systemic steroid therapy had a lower incidence of fever, and showed a higher mortality rate. CONCLUSION: Based on a nationwide epidemiological survey of SJS/TEN in Japan, we identified risk factors for sepsis and found that patients who had received steroid therapy for their underlying condition had a lower incidence of fever and a higher mortality rate.
Subject(s)
Sepsis , Stevens-Johnson Syndrome , Cross-Sectional Studies , Humans , Japan/epidemiology , Retrospective Studies , Risk Factors , Sepsis/complications , Sepsis/drug therapy , Sepsis/epidemiology , Steroids/adverse effects , Stevens-Johnson Syndrome/drug therapy , Stevens-Johnson Syndrome/epidemiology , Stevens-Johnson Syndrome/etiologyABSTRACT
BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening severe cutaneous adverse reactions (SCARs). The first national epidemiological survey of SJS/TEN was carried out in 2008. We conducted a new survey to identify changes from the previous survey. OBJECTIVE: The present survey aimed to estimate the number of SJS/TEN patients in Japan between 2016 and 2018 (primary survey) and to clarify clinical epidemiological profiles (secondary survey). METHODS: A primary survey asking for numbers of SJS/TEN patients during the study period was sent to 1205 institutions nationwide. A secondary survey was sent to institutions reporting SJS/TEN patients, seeking detailed information. RESULTS: Yearly prevalence per million was 2.5 for SJS and 1 for TEN. The secondary survey allowed analysis of 315 SJS cases and 174 TEN cases from 160 institutions. Mean age was 53.9 years in SJS, and 61.8 years in TEN. Mortality rate was 4.1 % for SJS and 29.9 % for TEN. In TEN, mean age and mortality rates had increased from the previous survey. The ratio of expected to observed mortality calculated by SCORTEN score was lowest with high-dose steroid therapy (0.40), followed by steroid pulse therapy (0.52). CONCLUSION: The present findings suggest that the mortality rate of TEN has increased because of increases in mean ages of patients and patients with malignant neoplasm as underlying disease. When comparing the ratio of expected mortality to actual mortality, high-dose steroid therapy achieved the greatest reduction in mortality.
Subject(s)
Glucocorticoids/administration & dosage , Stevens-Johnson Syndrome/epidemiology , Adult , Aged , Aged, 80 and over , Dose-Response Relationship, Drug , Female , Humans , Japan/epidemiology , Male , Middle Aged , Mortality , Prevalence , Retrospective Studies , Severity of Illness Index , Stevens-Johnson Syndrome/diagnosis , Stevens-Johnson Syndrome/drug therapy , Stevens-Johnson Syndrome/etiology , Treatment OutcomeABSTRACT
Agminated nevus refers to a clustered group of melanocytic nevi confined to a localized area of the body. It rarely involves acral skin, but recognition of acquired agminated nevus (AAN) in the acral area is clinically important because it may mimic acral lentiginous melanoma (ALM). However, acral AAN has only been described in a few case reports and its clinical characteristics remain unclear. We report three additional cases of acral AAN to further analyze the differential points between ALM. Clinical images, including those of dermoscopy, of three cases of acral AAN were reviewed. The lesions were located on the sole or lateral border of the foot. All acral AAN were flat and large in size (>20 mm in greatest dimension), and associated with asymmetry and irregular border. However, no parallel ridge pattern suggesting ALM was observed on dermoscopy. In two patients, the lesions on the sole were totally resected; microscopic evaluation of these two lesions confirmed junctional nests of banal melanocytes. AAN lesions on the sole with chronic mechanical pressure are slightly larger and more diffuse; thus, they may be more likely to be overdiagnosed as malignancy upon inspection than those in the non-acral area. Understanding the concept of the disease and careful dermoscopic evaluation leads to an accurate diagnosis.
Subject(s)
Melanoma , Nevus, Pigmented , Skin Neoplasms , Dermoscopy , Diagnosis, Differential , Humans , Melanoma/diagnosis , Nevus, Pigmented/diagnosis , Skin Neoplasms/diagnosisABSTRACT
The clinical classification of cutaneous adverse reactions by drugs should be clearly distinguished to avoid conceptual confusion and inconsistency. Although dermatologists appear to have established a roughly common consensus for cutaneous adverse reactions, some types are more rigorously defined than other, possibly misleading classifications. To assess the consensus on the clinical classifications, we investigated the concordance rate of diagnosis by Japanese experts through a snap visual inspection of various clinical pictures exhibiting erythema multiforme and maculopapular eruption types of cutaneous adverse reactions. The experts were shown images on a screen and were then asked to decide whether to classify cases as maculopapular eruption or erythema multiforme type, and the concordance rates were calculated. Overall, the mean concordance rate was 71.6% (standard deviation, 17.3%), and only 33.8% of cases had a 90% or more concordance rate. Our study shows that the determinations of erythema multiforme and maculopapular eruption types by the existing classification criteria were confusing even among experts, which prompted us to standardize the terminology. We propose clinically defining erythema multiforme type as generalized macules mainly of 1 cm or more with a tendency of elevation and coalescence, and maculopapular eruption type as generalized erythema other than erythema multiforme type. Currently, the clinical definitions of cutaneous adverse reactions are poorly described, which may be problematic upon analyzing large volumes of data. Our proposal for a new terminology will enhance the accuracy and consistency of information for the correct analysis of cutaneous adverse reactions.
Subject(s)
Dermatology/standards , Drug Eruptions/classification , Erythema Multiforme/diagnosis , Exanthema/diagnosis , Terminology as Topic , Drug Eruptions/diagnosis , Erythema Multiforme/chemically induced , Exanthema/chemically induced , Female , Humans , MaleABSTRACT
CYP2C9*3 and HLA-B alleles are reportedly associated with phenytoin-induced eruption in some East Asian populations; however, this finding is not readily applicable to the Japanese population. Thus, we aimed to investigate the risk alleles using samples and data from BioBank Japan. A total of 747 patients (24 cases and 723 tolerant controls) were selected for analysis. Case-control association studies were conducted, using CYP2C9*3, CYP2C9*27, CYP2C19*2, CYP2C19*3, and HLA-B allele genotype data. CYP2C9*3 carrier status was significantly associated with phenytoin-induced eruption (P = 0.0022, odds ratio 7.05, 95% confidence interval, 2.44-20.4). HLA-B*51:01 showed the most prominent association (P = 0.010, odds ratio 3.19, 95% confidence interval, 1.37-7.48). Including both of these features improved predictive performance, measured as area under the receiver operating characteristic curve, by 10%. CYP2C9*3 and HLA-B*51:01 allele carrier statuses are significantly associated with phenytoin-induced eruption; thus, checking this carrier status before prescription would decrease the incidence of phenytoin-induced eruption in clinical practice.
Subject(s)
Anticonvulsants/adverse effects , Cytochrome P-450 CYP2C9/genetics , Drug Eruptions/etiology , HLA-B51 Antigen/genetics , Phenytoin/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Alleles , Asian People/genetics , Biological Specimen Banks , Case-Control Studies , Child , Drug Eruptions/genetics , Female , Genotype , Humans , Japan , Male , Middle Aged , Retrospective Studies , Risk Factors , Young AdultSubject(s)
Cytomegalovirus/immunology , Dermatitis, Exfoliative/diagnosis , Drug Hypersensitivity Syndrome/diagnosis , Herpesvirus 6, Human/immunology , Administration, Oral , Aged , Cytomegalovirus/isolation & purification , Dermatitis, Exfoliative/drug therapy , Dermatitis, Exfoliative/immunology , Dermatitis, Exfoliative/virology , Diagnosis, Differential , Drug Hypersensitivity Syndrome/drug therapy , Drug Hypersensitivity Syndrome/immunology , Drug Hypersensitivity Syndrome/virology , Female , Herpesvirus 6, Human/isolation & purification , Humans , Lymphocyte Activation/drug effects , Lymphocyte Activation/immunology , Prednisolone/administration & dosage , Viral Load , Virus Activation/immunologySubject(s)
Adenocarcinoma, Sebaceous/diagnosis , Sebaceous Gland Neoplasms/diagnosis , Sebaceous Glands/pathology , Adenocarcinoma, Sebaceous/pathology , Aged , Biopsy , Dermoscopy , Diagnosis, Differential , Female , Humans , Keratosis, Actinic/diagnosis , Keratosis, Actinic/pathology , Sebaceous Gland Neoplasms/pathology , Sebaceous Glands/diagnostic imaging , Skin/diagnostic imaging , Skin/pathologyABSTRACT
Favus is a type of dermatophytosis known to produce yellow scutula around hair follicles. Most cases of this disease worldwide are infections of Trichophyton schoenleinii. Favus has rarely been reported in Japan throughout the last four decades, and T. schoenleinii has not been clinically isolated in any case during the period. Here, we report a case of favus of vellus hair observed in a 63-year-old Japanese woman. Fungal culture showed negative; however, we detected fungal elements in the crust and hair bulbs by Grocott staining. Pathogenic fungi were identified as T. schoenleinii by polymerase chain reaction-based DNA sequencing, targeting the internal transcribed spacer regions of the rRNA gene using the formalin-fixed, paraffin-embedded tissue sample. She was successfully treated with p.o. administration of terbinafine and topical application of luliconazole cream.
Subject(s)
Antifungal Agents/therapeutic use , Hair Follicle/microbiology , Tinea Favosa/diagnosis , Trichophyton/isolation & purification , Female , Hair Follicle/pathology , Humans , Japan , Middle Aged , Tinea Favosa/drug therapy , Tinea Favosa/microbiology , Treatment OutcomeABSTRACT
Pustules with facial and/or neck edema is one characteristic feature of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) at the early stage. Although several retrospective histopathologic studies on DIHS/DRESS have been reported, the detailed histopathologic findings of facial pustules for DIHS/DRESS are unavailable. We herein report a case of DIHS/DRESS with facial pustules that was histopathologically similar to eosinophilic pustular folliculitis (EPF). Eosinophilic infiltration into expanded follicles and sebaceous glands, which is highly characteristic of EPF, was detected in pustules due to DIHS/DRESS in this case. There are numerous pathophysiological similarities between DIHS/DRESS and EPF, which may cause their histopathologic similarity. Our findings suggest that facial pustules of DIHS/DRESS may histopathologically mimic EPF.
Subject(s)
Drug Hypersensitivity Syndrome , Eosinophilia , Eosinophils , Exanthema , Folliculitis , Hair Follicle , Skin Diseases, Vesiculobullous , Aged , Drug Hypersensitivity Syndrome/metabolism , Drug Hypersensitivity Syndrome/pathology , Eosinophilia/metabolism , Eosinophilia/pathology , Eosinophils/metabolism , Eosinophils/pathology , Exanthema/metabolism , Exanthema/pathology , Face/pathology , Folliculitis/metabolism , Folliculitis/pathology , Hair Follicle/metabolism , Hair Follicle/pathology , Humans , Male , Skin Diseases, Vesiculobullous/metabolism , Skin Diseases, Vesiculobullous/pathologyABSTRACT
Drug-induced hypersensitivity syndrome (DIHS), also referred to as drug reaction with eosinophilia and systemic symptoms (DRESS), is a multi-organ systemic drug reaction characterized by hematological abnormalities and reactivation of human herpesvirus-6 (HHV-6). DIHS/DRESS is typically associated with a limited number of drugs, such as the anticonvulsants. Our group has treated 12 patients for DIHS/DRESS due to lamotrigine (LTG), but their presentation differed from that of patients with DIHS/DRESS caused by other drugs. The aim of the present study was to identify significant differences between DIHS/DRESS caused by LTG versus other drugs. We retrospectively reviewed data of 12 patients with DIHS/DRESS caused by LTG and 32 patients with DIHS/DRESS due to other drugs. The increase in alanine aminotransferase level was significantly milder in the LTG group than the DIHS/DRESS group due to other drugs. The percentage of atypical lymphocytes in the blood during DIHS/DRESS was lower in the LTG group. Serum levels of lactate dehydrogenase and thymus and activation-regulated chemokine were also lower in the LTG group. There were fewer DIHS/DRESS patients with HHV-6 reactivation in the LTG group than in the group treated with other drugs. Lymphocyte transformation after DIHS/DRESS onset was faster in the LTG group. The two groups did not differ with respect to the interval from first drug intake to rash, white blood cell count, blood eosinophilia or DRESS score. There were no significant histopathological differences between the two groups. The features of LTG-associated DIHS/DRESS and DIHS/DRESS due to other drugs differ.
Subject(s)
Anticonvulsants/adverse effects , Drug Hypersensitivity Syndrome/etiology , Lamotrigine/adverse effects , Adult , Drug Hypersensitivity Syndrome/blood , Epilepsy/drug therapy , Female , Humans , Leukocyte Count , Male , Middle Aged , Retrospective StudiesABSTRACT
OBJECTIVE: To study the effect of Jumihaidokuto (Shi-Wei-Bai-Du-Tang, ) in the management of chronic spontaneous urticaria. METHODS: A randomized two-arm, parallel group study was conducted to compare the effect of Jumihaidokuto (6 g daily) with a control for 8 weeks. Concomitant therapy (e.g., antihistamines) was continued. Twenty-one subjects with severe chronic urticaria were enrolled in this study. The primary treatment outcome was the severity score proposed by the Japanese Dermatological Association. Secondary outcomes were quality of life (Skindex-16), itch intensity (Visual Analogue Scale), and patients' subjective disability due to wheal or itch. After the subjects were randomly assigned to groups by block randomization, 10 received Jumihaidokuto, and 11 did not. All subjects had already taken antihistamines. RESULTS: Improvement was significant when comparing the severity score of the Jumihaidokuto group with that of the control group (P<0.01). Skindex-16 values for both groups gradually decreased in the same fashion. CONCLUSION: Concomitant use of Jumihaidokuto with antihistamine was more effective than antihistamine alone in the management of chronic idiopathic urticaria. (Trial Registration No. UMIN000007251).
Subject(s)
Chronic Urticaria/drug therapy , Histamine Antagonists/administration & dosage , Plant Extracts/administration & dosage , Adult , Aged , Chronic Urticaria/pathology , Drug Therapy, Combination/methods , Female , Humans , Male , Middle Aged , Plant Extracts/pharmacology , Quality of Life , Severity of Illness Index , Treatment Outcome , Young AdultSubject(s)
Amino Acyl-tRNA Synthetases/immunology , Autoantibodies/blood , Myositis/complications , Raynaud Disease/immunology , Skin Ulcer/immunology , Adult , Autoantibodies/immunology , Female , Humans , Myositis/blood , Myositis/immunology , Raynaud Disease/blood , Raynaud Disease/pathology , Recurrence , Skin/immunology , Skin/pathology , Skin Ulcer/blood , Skin Ulcer/pathologySubject(s)
Circulating MicroRNA/blood , Drug Hypersensitivity Syndrome/virology , Herpesvirus 6, Human/genetics , RNA, Viral/blood , Virus Activation , Case-Control Studies , Circulating MicroRNA/genetics , Drug Hypersensitivity Syndrome/blood , Drug Hypersensitivity Syndrome/diagnosis , Genetic Markers , Herpesvirus 6, Human/pathogenicity , Humans , RNA, Viral/genetics , Time Factors , Up-RegulationSubject(s)
Gene Rearrangement , Nevus, Epithelioid and Spindle Cell/genetics , Protein-Tyrosine Kinases/genetics , Proto-Oncogene Proteins/genetics , Skin Neoplasms/genetics , Adult , Ear , Humans , Japan , Male , Nevus, Epithelioid and Spindle Cell/diagnosis , Nevus, Epithelioid and Spindle Cell/pathology , Skin/pathology , Skin Neoplasms/diagnosis , Skin Neoplasms/pathologySubject(s)
Melanoma/diagnostic imaging , Melanoma/pathology , Skin Neoplasms/diagnostic imaging , Skin Neoplasms/pathology , Ultrasonography, Doppler, Color/methods , Adult , Aged , Aged, 80 and over , Biopsy, Needle , Female , Humans , Immunohistochemistry , Male , Melanoma/blood supply , Melanoma/surgery , Middle Aged , Preoperative Care/methods , Regional Blood Flow , Sampling Studies , Sensitivity and Specificity , Skin/blood supply , Skin/pathology , Skin Neoplasms/blood supply , Skin Neoplasms/surgery , Melanoma, Cutaneous MalignantABSTRACT
Microneedle (MN) patches have great potential as transcutaneous vaccine delivery devices because MNs can effectively deliver vaccine antigen into the skin through the micropores formed in the stratum corneum by low-invasive and painless skin puncturing. This study aims to develop novel double-decker MN patches which have not only high safety and efficacy but also broad applicability to various vaccine antigens. We developed two types of MN patches (PGA-MN and Nylon-MN) that are made from polyglycolic acid and Nylon-6. In pre-clinical studies, both MN patches could demonstrably deliver antigens into resected human dermal tissue, prolong antigen deposition and increase antigen-specific IgG levels after vaccination compared with conventional injections. We demonstrated both MN patches could be safely applied to human skin because no broken MNs or significant skin irritation were observed after applications in the clinical research. PGA-MN was suggested to be superior to Nylon-MN regarding human skin puncturability based on measurements of transepidermal water loss and needle failure force. A high content of tetravalent influenza hemagglutinin antigens loaded on PGA-MN could stably maintain HA titers at 35°C for 1year. Overall, double-decker MN patches can reliably and safely puncture human skin and are promising as effective transcutaneous vaccine delivery devices.